Pacira Pharmaceuticals, Inc.

Form 4

May 08, 2013

# FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

**OMB APPROVAL** 

**OMB** 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per response...

0.5

Section 16. Form 4 or Form 5 obligations may continue. See Instruction

Check this box

if no longer

subject to

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

Stock

(Print or Type Responses)

1. Name and A EVNIN LU	2. Issuer Name <b>and</b> Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [PCRX]					5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)					
(Last) (First) (Middle)  C/O MPM ASSET  MANAGEMENT, 200  CLARENDON STREET, 54TH  FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 04/12/2013					X Director Officer (given below)	10%	6 Owner er (specify	
	(Street) 4. If Ame			ndment, Da nth/Day/Year	Č			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative S	Securi	ties Acq	uired, Disposed o	of, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, any (Month/Day/Year)		emed on Date, if	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)  (A) or				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of	
Common Stock	04/12/2013			Code V	Amount 37,192 (1)	(D)	Price \$ 2.69	1,317,671	I	See Footnote (2) (3)	
Common Stock	04/12/2013			S <u>(4)</u>	3,416 (4)	D	\$ 29.3	1,314,255	Ι	See Footnote (3) (5)	
Common								22,746	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orderivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Warrants (Right to Buy)	\$ 2.69	04/12/2013		X		37,192 (1)	01/22/2009	01/21/2014	Common Stock	37,192

## **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

EVNIN LUKE C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116

X

### **Signatures**

/s/ Luke Evnin 05/08/2013

\*\*Signature of Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The warrants were held and exercised as follows: 34,858 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 1,343 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG") and 991 by MPM Asset Management Investors BV4 LLC ("AM BV4"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP and BV IV KG and BV LLC is the manager of AM BV4. The Reporting Person is a member of BV LLC.
- (2) The shares are held as follows: 1,234,997 by BV IV QP, 47,582 by BV IV KG and 35,092 by AM BV4. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Reporting Owners 2

#### Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

- Does not reflect previously reported transactions that occurred after April 12, 2013 and the Form 4s filed by the Reporting Person reporting such transactions failed to take into account the transactions reported hereby. Accordingly, the Form 4s filed by the Reporting Person on April 18, 2013 and April 29, 2013 understated the number of shares beneficially owned following the transactions reported therein by an aggregate of 33,776 shares.
- On April 12, 2013, the following warrants to purchase shares of PCRX common stock were exercised for \$2.69 per share: 34,858 by BV (4) IV QP, 1,343 by BV IV KG and 991 by AM BV4. The exercise price was paid on a cashless basis, resulting in PCRX's withholding of the following warrant shares to pay the exercise price: 3,201 for BV IV QP, 124 for BV IV KG and 91 for AM BV4.
- (5) The shares are held as follows: 1,231,796 by BV IV QP, 47,458 by BV IV KG and 35,001 by AM BV4. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.